2 Obamacare Supreme Court Ruling "Losers" That Didn't Really Lose

Did these two contraceptive-drug makers lose with this week's Supreme Court ruling on Obamacare? Not really.

Jul 1, 2014 at 1:47PM

Put Obamacare in the losers' bracket this week.

On Monday, the U.S. Supreme Court announced a 5-4 decision that prevents the federal government from requiring under the Affordable Care Act that some companies to offer health insurance coverage for specific types of contraceptives for which their owners have religious objections. Clear winners included Hobby Lobby and Conestoga Wood Specialties of Pennsylvania, the two closely held private companies involved in the case.

A couple of other companies were also directly affected by the Supreme Court ruling, as they sell emergency contraceptives. Actavis (NYSE:AGN) sells ella, while Teva Pharmaceutical (NYSE:TEVA) markets Plan B. Both birth control drugs encountered religious objections from Hobby Lobby and Conestoga.Now the highest court in the land has ruled that other closely held companies could opt out of paying for the drugs for employees. That includes as much as 90% of employers in the U.S. and over half of all employees.  

So should Actavis and Teva also be placed in the losers' bracket following the ruling? Probably not.

Neither stock took much of a hit from the potentially far-reaching decision. Actavis on Monday closed down by a paltry 0.1%. Teva fell by only 0.8%. Those small declines don't seem to reflect a worried investor community.

Why did the market yawn? For one thing, there is reason to suspect that the ripple impact won't be very large. Around 96% of U.S. small businesses are already exempt from Obamacare because they have fewer than 50 employees.

It is unknown how many employers that must comply with Obamacare could change their insurance plans as a result of the Supreme Court ruling. A Kaiser Family Foundation survey found that 85% of larger organizations covered contraceptives prior to implementation of the Affordable Care Act. However, it should be noted that this poll didn't include details about coverage of emergency contraceptives such as ella and Plan B. 

There is a bigger reason to believe Actavis and Teva won't be affected significantly by the court's decision. The reality is that the controversial birth control drugs aren't critical for either company's success.

Actavis counts 321 different product groups in its lineup. Ella doesn't even get a footnote in the company's annual regulatory filing. Teva boasts over 55,000 product variants. All of the company's women's health products combined accounted for less than 3% of Teva's total revenue last year. 

For Actavis, the relative importance of ella will soon be diluted even further. The company in February announced plans to acquire Forest Laboratories (NYSE:FRX) for $25 billion. The U.S. Federal Trade Commission voted on Monday to approve the acquisition.  

While Actavis and Teva aren't really losers from the Supreme Court decision this week, that doesn't necessarily make both of them winners. Teva's shares are up 30% so far this year, but the drugmaker faces steep challenges ahead as generic rivals to its largest revenue generator, Copaxone, begin competing for market share.

Actavis, however, appears to be a different story. Its stock has climbed even more than Teva's in 2014 and could still have room to run. The buyout of Forest Labs could create as much as $1 billion annually in operational and tax synergies. Actavis' growth prospects, along with positives from its latest acquisition, should keep this stock in the winners' bracket.  

1 potentially game-changing stock that could make you a winner
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Keith Speights has no positions in any stocks mentioned. The Motley Fool recommends Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers